Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA-based patient classifier
KRAS mutations are among the most prevalent oncogenic drivers [...]
KRAS mutations are among the most prevalent oncogenic drivers [...]
Tempus’ live webinar featuring Rafael Rosengarten [...]
New results from translational, clinical, and real-world studies showcase [...]
Schedule a meeting Genialis™ Supermodel - [...]
KRAS mutations drive approximately 25% of human cancers, resulting [...]
The WEE1 kinase is a central regulator of G2/M [...]
"In cancer treatment, a simple yes or no isn’t [...]
Genialis’ Upcoming Events Genialis on LinkedIn [...]
Genialis’ Chief Discovery Officer, Luka Ausec, recently joined Tjaša [...]
Genialis extends its collaboration with Debiopharm [...]